136 related articles for article (PubMed ID: 37244450)
21. Effect of variations in the amounts of P-glycoprotein (ABCB1), BCRP (ABCG2) and CYP3A4 along the human small intestine on PBPK models for predicting intestinal first pass.
Bruyère A; Declèves X; Bouzom F; Ball K; Marques C; Treton X; Pocard M; Valleur P; Bouhnik Y; Panis Y; Scherrmann JM; Mouly S
Mol Pharm; 2010 Oct; 7(5):1596-607. PubMed ID: 20604570
[TBL] [Abstract][Full Text] [Related]
22. Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice.
Marchetti S; de Vries NA; Buckle T; Bolijn MJ; van Eijndhoven MA; Beijnen JH; Mazzanti R; van Tellingen O; Schellens JH
Mol Cancer Ther; 2008 Aug; 7(8):2280-7. PubMed ID: 18723475
[TBL] [Abstract][Full Text] [Related]
23. Tetrahydrocannabinol and Its Major Metabolites Are Not (or Are Poor) Substrates or Inhibitors of Human P-Glycoprotein [ATP-Binding Cassette (ABC) B1] and Breast Cancer Resistance Protein (ABCG2).
Chen X; Unadkat JD; Mao Q
Drug Metab Dispos; 2021 Oct; 49(10):910-918. PubMed ID: 34326138
[TBL] [Abstract][Full Text] [Related]
24. Induction of drug efflux protein expression by venlafaxine but not desvenlafaxine.
Bachmeier CJ; Beaulieu-Abdelahad D; Ganey NJ; Mullan MJ; Levin GM
Biopharm Drug Dispos; 2011 May; 32(4):233-44. PubMed ID: 21446053
[TBL] [Abstract][Full Text] [Related]
25. Rhinacanthin-C Mediated Herb-Drug Interactions with Drug Transporters and Phase I Drug-Metabolizing Enzymes.
Dunkoksung W; Vardhanabhuti N; Siripong P; Jianmongkol S
Drug Metab Dispos; 2019 Oct; 47(10):1040-1049. PubMed ID: 31399508
[TBL] [Abstract][Full Text] [Related]
26. Biochemical interaction of anti-HCV telaprevir with the ABC transporters P-glycoprotein and breast cancer resistance protein.
Fujita Y; Noguchi K; Suzuki T; Katayama K; Sugimoto Y
BMC Res Notes; 2013 Nov; 6():445. PubMed ID: 24196382
[TBL] [Abstract][Full Text] [Related]
27. Development of a novel
Zhang J; Penny J; Lu JR
Int J Food Sci Nutr; 2020 Aug; 71(5):549-562. PubMed ID: 31847617
[TBL] [Abstract][Full Text] [Related]
28. Using novobiocin as a specific inhibitor of breast cancer resistant protein to assess the role of transporter in the absorption and disposition of topotecan.
Su Y; Hu P; Lee SH; Sinko PJ
J Pharm Pharm Sci; 2007; 10(4):519-36. PubMed ID: 18261372
[TBL] [Abstract][Full Text] [Related]
29. Usefulness of Human Jejunal Spheroid-Derived Differentiated Intestinal Epithelial Cells for the Prediction of Intestinal Drug Absorption in Humans.
Michiba K; Maeda K; Shimomura O; Miyazaki Y; Hashimoto S; Oda T; Kusuhara H
Drug Metab Dispos; 2022 Mar; 50(3):204-213. PubMed ID: 34992074
[TBL] [Abstract][Full Text] [Related]
30. Effects of the antiretroviral drug 2'-deoxy-2'-β-fluoro-4'-azidocytidine (FNC) on P-gp, MRP2 and BCRP expressions and functions.
Liu Y; Wang Y; Peng Y; Liu B; Ma F; Jiang J; Wang Q; Chang J
Pharmazie; 2018 Sep; 73(9):503-507. PubMed ID: 30223932
[TBL] [Abstract][Full Text] [Related]
31. Development and characterization of rat duodenal organoids for ADME and toxicology applications.
Hedrich WD; Panzica-Kelly JM; Chen SJ; Strassle B; Hasson C; Lecureux L; Wang L; Chen W; Sherry T; Gan J; Davis M
Toxicology; 2020 Dec; 446():152614. PubMed ID: 33199268
[TBL] [Abstract][Full Text] [Related]
32. The short-chain fatty acid butyrate is a substrate of breast cancer resistance protein.
Gonçalves P; Gregório I; Martel F
Am J Physiol Cell Physiol; 2011 Nov; 301(5):C984-94. PubMed ID: 21775706
[TBL] [Abstract][Full Text] [Related]
33. Exposure to High-Altitude Environment Is Associated with Drug Transporters Change: microRNA-873-5p-Mediated Alteration of Function and Expression Levels of Drug Transporters under Hypoxia.
Duan Y; Bai X; Yang J; Zhou Y; Gu W; Liu G; Wang Q; Zhu J; La L; Li X
Drug Metab Dispos; 2022 Feb; 50(2):174-186. PubMed ID: 34844996
[TBL] [Abstract][Full Text] [Related]
34. Recent advances in the in vitro and in vivo methods to assess impact of P-glycoprotein and breast cancer resistance protein transporters in central nervous system drug disposition.
Chatterjee S; Deshpande AA; Shen H
Biopharm Drug Dispos; 2023 Feb; 44(1):7-25. PubMed ID: 36692150
[TBL] [Abstract][Full Text] [Related]
35. Solitary Inhibition of the Breast Cancer Resistance Protein Efflux Transporter Results in a Clinically Significant Drug-Drug Interaction with Rosuvastatin by Causing up to a 2-Fold Increase in Statin Exposure.
Elsby R; Martin P; Surry D; Sharma P; Fenner K
Drug Metab Dispos; 2016 Mar; 44(3):398-408. PubMed ID: 26700956
[TBL] [Abstract][Full Text] [Related]
36. The role of efflux transporters on the transport of highly toxic aconitine, mesaconitine, hypaconitine, and their hydrolysates, as determined in cultured Caco-2 and transfected MDCKII cells.
Ye L; Yang X; Yang Z; Gao S; Yin T; Liu W; Wang F; Hu M; Liu Z
Toxicol Lett; 2013 Feb; 216(2-3):86-99. PubMed ID: 23200901
[TBL] [Abstract][Full Text] [Related]
37. Differential selectivity of efflux transporter inhibitors in Caco-2 and MDCK-MDR1 monolayers: a strategy to assess the interaction of a new chemical entity with P-gp, BCRP, and MRP2.
Mease K; Sane R; Podila L; Taub ME
J Pharm Sci; 2012 May; 101(5):1888-97. PubMed ID: 22359351
[TBL] [Abstract][Full Text] [Related]
38. Species difference in brain penetration of P-gp and BCRP substrates among monkey, dog and mouse.
Kido Y; Nanchi I; Fusamae Y; Matsuzaki T; Akazawa T; Sawada H; Iwasaki M; Nishida K; Tsuchiya E; Okuda T
Drug Metab Pharmacokinet; 2022 Feb; 42():100426. PubMed ID: 34974334
[TBL] [Abstract][Full Text] [Related]
39. Breast cancer resistance protein (ABCG2) and drug disposition: intestinal expression, polymorphisms and sulfasalazine as an in vivo probe.
Urquhart BL; Ware JA; Tirona RG; Ho RH; Leake BF; Schwarz UI; Zaher H; Palandra J; Gregor JC; Dresser GK; Kim RB
Pharmacogenet Genomics; 2008 May; 18(5):439-48. PubMed ID: 18408567
[TBL] [Abstract][Full Text] [Related]
40. In vitro characterization of axitinib interactions with human efflux and hepatic uptake transporters: implications for disposition and drug interactions.
Reyner EL; Sevidal S; West MA; Clouser-Roche A; Freiwald S; Fenner K; Ullah M; Lee CA; Smith BJ
Drug Metab Dispos; 2013 Aug; 41(8):1575-83. PubMed ID: 23729661
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
